^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    STAT5B (Signal Transducer And Activator Of Transcription 5B)

    i
    Other names: STAT5B, Signal Transducer And Activator Of Transcription 5B, Transcription Factor STAT5B, STAT5
    24d
    Genomic Landscape of Thymic Carcinoma: A Large-Scale Analysis of Somatic Mutations, Demographic Disparities, and Metastatic Drivers from the AACR Project GENIE® Cohort. (PubMed, Curr Issues Mol Biol)
    The identification of sex-associated and race-associated mutational patterns, together with the enrichment of MTOR alterations in recurrent and metastatic disease, highlights biologically plausible mechanisms of progression and potential therapeutic vulnerabilities. These findings support the value of comprehensive genomic profiling in TC and emphasize the need for prospective, multi-omic studies to validate these observations and guide the development of more personalized treatment strategies.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • mTOR (Mechanistic target of rapamycin kinase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • STAT5B (Signal Transducer And Activator Of Transcription 5B)
    |
    CDKN2A deletion
    1m
    Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. (PubMed, Blood Neoplasia)
    Continued studies evaluating JAK inhibitors in patients with T-PLL are warranted. This trial was registered at www.clinicaltrials.gov as #NCT03989466.
    Clinical • P1 data • Journal
    |
    JAK3 (Janus Kinase 3) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • TCL1A (TCL1 Family AKT Coactivator A) • IL2RG (Interleukin 2 Receptor Subunit Gamma)
    |
    Campath (alemtuzumab) • itacitinib (INCB039110)
    3ms
    Stafib-2-CR: an Improved Nanomolar and Selective Inhibitor of the Transcription Factor STAT5b Developed by Conformational Restriction of Stafib-2. (PubMed, Chemistry)
    The best conformationally restricted Stafib-2 analogue 8b (dubbed Stafib-2-CR) displayed approximately threefold higher activity against STAT5b than Stafib-2, associated with higher selectivity over STAT5a. Its cell-permeable prodrug 17 (dubbed Pomstafib-2-CR) inhibits phosphorylation of STAT5b in cultured human leukemia cells with slightly higher activity and selectivity over STAT5a than Pomstafib-2, the prodrug corresponding to Stafib-2.
    Journal
    |
    STAT5B (Signal Transducer And Activator Of Transcription 5B)
    3ms
    The Prognostic Role of STAT5B Across Cancer Types and Comparative Analysis with STAT5A: A Systematic Review. (PubMed, Biomolecules)
    Elevated STAT5B expression is associated with improved survival in multiple cancers, supporting a potential tumor-suppressive role distinct from STAT5A. These findings underscore the importance of isoform-specific STAT5 evaluation in cancer prognosis and suggest that STAT5B may serve as a potential biomarker and therapeutic target.
    Clinical • Review • Journal
    |
    STAT5B (Signal Transducer And Activator Of Transcription 5B) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    3ms
    Asymptomatic T prolymphocytic leukemia: case report and literature review. (PubMed, Einstein (Sao Paulo))
    Standard therapies include alemtuzumab-based regimens and hematopoietic stem cell transplantation, although relapse rates remain high. This case underscores the need to recognize indolent presentations of T-cell prolymphocytic leukemia that may be managed conservatively. Further research is required to identify prognostic markers and optimize therapeutic strategies.
    Review • Journal
    |
    ATM (ATM serine/threonine kinase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • TCL1A (TCL1 Family AKT Coactivator A)
    |
    ATM mutation
    |
    Campath (alemtuzumab)
    5ms
    Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma. (PubMed, Leukemia)
    Unsupervised analyses of mutations, transcription, and methylation profiles concordantly segregated EATLs from MEITLs. In summary, the distinctive genetic, epigenetic, and expression footprints of EATL and MEITL established by this study expand disease-defining features, have diagnostic implications, and provide a rationale for targeted therapies.
    Journal • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ARID1A (AT-rich interaction domain 1A) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • IDO1 (Indoleamine 2,3-dioxygenase 1) • JAK3 (Janus Kinase 3) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • H3-3A (H3.3 Histone A)
    |
    ARID1A mutation • TET2 mutation
    5ms
    Transcriptome Analysis Identifies Functional and Prognostic Hypoxia-Associated Genes in Multiple Myeloma. (PubMed, Int J Lab Hematol)
    Taken together, our findings may contribute to the treatment and prognosis prediction of MM patients.
    Journal
    |
    HMOX1 (Heme Oxygenase 1) • SDC1 (Syndecan 1) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • BNIP3L (BCL2 Interacting Protein 3 Like) • EGLN1 (Egl-9 Family Hypoxia Inducible Factor 1)
    5ms
    HEM-iSMART C: HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=26, Recruiting, Princess Maxima Center for Pediatric Oncology | Trial completion date: Oct 2031 --> Feb 2032 | Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2031 --> Feb 2032
    Enrollment open • Trial completion date • Trial primary completion date
    |
    JAK2 (Janus kinase 2) • CRLF2 (Cytokine Receptor Like Factor 2) • JAK1 (Janus Kinase 1) • IL7R (Interleukin 7 Receptor) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • P2RY8 (P2Y Receptor Family Member 8) • EPOR (Erythropoietin Receptor) • PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) • SH2B3 (SH2B Adaptor Protein 3) • DDX3X (DEAD-Box Helicase 3 X-Linked) • USP9X (Ubiquitin Specific Peptidase 9 X-Linked)
    |
    Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • cyclophosphamide
    6ms
    Monomorphic epitheliotropic intestinal T-cell lymphoma: a clinicopathological and genetic mutation characteristics analysis of forty-two cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
    Its clinical manifestations are diverse, and diagnosis primarily relies on a comprehensive assessment of pathological morphology, immunohistochemical profiles, and EBV infection status, supplemented by genetic testing if necessary. At present, there is no effective treatment, and its overall prognosis is poor.
    Retrospective data • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CREBBP (CREB binding protein) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • CD4 (CD4 Molecule) • JAK3 (Janus Kinase 3) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • GZMB (Granzyme B) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • PRF1 (Perforin 1)
    |
    TP53 mutation
    6ms
    A Rare Case of Renal Failure Caused by T-Cell Prolymphocytic Leukaemia Infiltration. (PubMed, Case Rep Hematol)
    He required haemodialysis, but was treated with pulsed methylprednisolone and alemtuzumab, with excellent renal recovery, although remission was not achieved. This case demonstrates that renal leukaemic infiltration must be considered in T-PLL patients with rapidly progressive renal failure, and that solid organ invasion should not contraindicate timely commencement of T-PLL-directed therapy with alemtuzumab.
    Journal
    |
    STAT5B (Signal Transducer And Activator Of Transcription 5B)
    |
    Campath (alemtuzumab)
    6ms
    Identification and visualization of fusion gene subtypes in APL using spatial attention mechanisms in vision models. (PubMed, Front Oncol)
    The attention maps also enhance the model's interpretability. Such a novel and rapid diagnostic approach for APL subtypes, which achieves high - precision identification and pixel - level visualization, holds significant clinical value.
    Journal
    |
    NPM1 (Nucleophosmin 1) • RARA (Retinoic Acid Receptor Alpha) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • PML (Promyelocytic Leukemia) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • RARG (Retinoic Acid Receptor Gamma)
    |
    PML-RARA fusion
    6ms
    Oligodendrocyte-Specific STAT5B Overexpression Ameliorates Myelin Impairment in Experimental Models of Parkinson's Disease. (PubMed, Cells)
    DNMT3A inhibited the expression of STAT5B by affecting its methylation, which reduced the transcription of MBP, caused oligodendrocyte myelin damage, and eventually led to dopamine neuron damage and motor dysfunction in an MPTP-induced mouse model. This DNMT3A-STAT5B-MBP axis underlies PD-associated myelin damage, connecting epigenetic dysregulation with oligodendrocyte dysfunction and subsequent PD pathogenesis.
    Journal
    |
    DNMT3A (DNA methyltransferase 1) • SOX10 (SRY-Box 10) • STAT5B (Signal Transducer And Activator Of Transcription 5B)